This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic's (MDT) Cryoablation Catheters Get FDA Expanded Nod
by Zacks Equity Research
Medtronic's (MDT) Cardiac Cryoablation is the only ablation catheter approved to treat pediatric AVNRT.
Here's Why You Should Hold on to STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) on its better-than-expected earnings in the fiscal third quarter and the ongoing integration of the Cantel Medical business.
Integer Holdings (ITGR) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter results reflect robust segmental performances besides strength in the majority of the product lines.
Quidel (QDEL) Q4 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Despite robust revenues from COVID-19 products, Quidel (QDEL) records an overall soft Q4 performance.
West Pharmaceutical (WST) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter earnings reflect strength in the Proprietary Products segment and margin expansion.
Phibro (PAHC) Up 17.1% Since Q2 Earnings: What's Driving It?
by Zacks Equity Research
Phibro's (PAHC) stock rallies on continued demand for its products globally and raised 2022 guidance.
West Pharmaceutical Services (WST) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 6.25% and 3.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Illumina's (ILMN) GRAIL, Point32Health Unite to Offer MCED Test
by Zacks Equity Research
Illumina's (ILMN) GRAIL Galleri MCED test detects more than 50 types of cancer and can predict the origin of the cancer signal with high accuracy across multiple cancer types.
Zimmer Biomet (ZBH) Business Hurt by China VBP, Price Woe
by Zacks Equity Research
According to Zimmer Biomet (ZBH), severe customer staffing shortages and a more-than-anticipated impact of China VBP lead to dismal Q4 revenues.
LabCorp (LH) Expands Clinical Laboratory Services With New Pact
by Zacks Equity Research
LabCorp's (LH) recent collaboration will enable it to administer Ascension's hospital-based laboratories in 10 states and purchase select assets of the health system's outreach laboratory business.
What's in Store for West Pharmaceutical's (WST) Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic's (HOLX) impressive Breast Imaging and Interventional Breast Solutions business performance.
Zimmer Biomet (ZBH) Opens New ZBEdge Centre in Singapore
by Zacks Equity Research
Zimmer Biomet (ZBH) CEC will function as the interface between healthcare professionals and the company through engaging and interactive training across all product portfolios.
DexCom (DXCM) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth and solid new customer additions.
West Pharmaceutical Services (WST) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in the Animal Health business and dental business.
West Pharmaceutical Services (WST) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, West Pharmaceutical Services (WST) closed at $400.69, marking a -0.01% move from the previous day.
IDEXX's (IDXX) CAG Diagnostic Sales Gain, Cost Woe Stays
by Zacks Equity Research
IDEXX (IDXX) witnesses continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) on increased demand for sleep and respiratory care devices on steady recovery of markets from COVID-19 impacts.
Illumina (ILMN) to Address Nasopharynx Cancer With New Pact
by Zacks Equity Research
Illumina's (ILMN) recent collaboration will fuel initiatives that enhance health outcomes for people living with nasopharynx cancer and advance the development of personalized treatment.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business. However, forex woes persist.
West Pharmaceutical Services (WST) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, West Pharmaceutical Services (WST) closed at $393.22, marking a +0.05% move from the previous day.
Here's Why You Should Add Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics' (DGX) improvement in base business and raised 2021 outlook.
West Pharmaceutical Services (WST) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, West Pharmaceutical Services (WST) closed at $378.36, marking a -1.35% move from the previous day.